Primary human papillomavirus screening for cervical cancer in the United States - US Food and Drug Administration approval, clinical trials, and where we are today

Cancer Cytopathology

Volumn 122, Issue 10, 2014, Pages 720-729

  Nayar, Ritu ^a   Goulart, Robert A ^b   Tiscornia Wasserman, Patricia G ^c   Davey, Diane Davis ^d  

^a NORTHWESTERN UNIVERSITY   (United States)

^b MA 01104   (United States)

^c Department of Medicine   (United States)

^d UNIVERSITY OF CENTRAL FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER GRADING; CANCER SCREENING; DIAGNOSTIC TEST APPROVAL; FEMALE; FOOD AND DRUG ADMINISTRATION; HIGH RISK POPULATION; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; NONHUMAN; NOTE; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRIORITY JOURNAL; QUALITY CONTROL; SENSITIVITY AND SPECIFICITY; SQUAMOUS INTRAEPITHELIAL LESION OF THE CERVIX; UNITED STATES; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS CAPSID; WART VIRUS; ADOLESCENT; ADULT; CLINICAL TRIAL (TOPIC); COLPOSCOPY; COMPARATIVE STUDY; CYTODIAGNOSIS; EARLY DIAGNOSIS; FORECASTING; INCIDENCE; LABORATORY DIAGNOSIS; MASS SCREENING; MIDDLE AGED; NEEDLE BIOPSY; NEEDS ASSESSMENT; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; PROCEDURES; RISK ASSESSMENT; TRENDS; UTERINE CERVICAL NEOPLASMS; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; BIOPSY, NEEDLE; CLINICAL TRIALS AS TOPIC; COLPOSCOPY; CYTODIAGNOSIS; EARLY DETECTION OF CANCER; FALSE NEGATIVE REACTIONS; FEMALE; FORECASTING; HUMANS; INCIDENCE; MASS SCREENING; MIDDLE AGED; NEEDS ASSESSMENT; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTIONS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84921959466     PISSN: 1934662X     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.21480     Document Type: Note

References (47)

1. US Department of Health and Human Services, National Institutes of Health. Cervical Cancer Fact Sheet [updated, May 2013]. Washington, DC: US Department of Health and Human Services; 2013.
2. The 1988 Bethesda System for reporting cervical/vaginal cytological diagnoses. National Cancer Institute Workshop. JAMA. 1989; 262: 931-934.
3. Wright TC Jr, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ,. ASCCP-Sponsored Consensus Conference. 2001 Consensus Guidelines for the Management of Women with Cytological Abnormalities. JAMA. 2002; 287: 2120-2129.
4. Smith J, Lindsay L, Hoots B, et al., Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007; 121: 621-632.
5. Sherman ME, Solomon D, Schiffman M,; for the ASCUS/LSIL Triage Study Group. Qualification of ASCUS: a comparison of equivocal LSIL and equivocal HSIL cervical cytology in the ASCUS/LSIL Triage Study. Am J Clin Pathol. 2001; 116: 386-394.
6. Rijkaart DC, Berkhof J, van Kemenade FJ, et al., HPV DNA testing in population-based cervical screening (VUSA-Screen study): results and implications. Br J Cancer. 2012; 106: 975-981.
7. Leinonen MK, Nieminen P, Lonnberg S, et al., Detection rates of precancerous and cancerous cervical lesions within 1 screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland [serial online]. BMJ. 2012; 29: 345.
8. Gyllensten U, Gustavsson I, Lindell M, Wilander E,. Primary high-risk HPV screening for cervical cancer in post-menopausal women. Gynecol Oncol. 2012; 125: 343-345.
9. Ogilvie GS, Krajden M, van Niekerk DJ, et al., Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial-the HPV FOCAL Study. Br J Cancer. 2012; 107: 1917-1924.
10. Ronco G, Dillner J, Elfstrom KM, et al., International HPV Screening Working Group. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of 4 European randomised controlled trials. Lancet. 2014; 383: 524-532.
11. Sherman ME, Lorincz AT, Scott DR, et al., Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst. 2003; 95: 46-52.
12. Katki HA, Kinney WK, Fetterman B, et al., Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol. 2011; 12: 663-672.
13. Saslow D, Solomon D, Lawson HW, et al., American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol. 2012; 137: 516-542.
14. Gattoc L, Nair N, Ault K,. Human papillomavirus vaccination: current indications and future directions. Obstet Gynecol Clin North Am. 2013; 40: 177-197.
15. US Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health, Medical Devices Advisory Committee. Meeting materials of the Microbiology Devices Panel, March 12, 2014. Available at: http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/MicrobiologyDevicesPanel/ucm388531.htm. Accessed July 15, 2014.
16. Simon K, Kondratovich M,. FDA presentation March 12, 2014: Microbiology Devices Advisory Committee Meeting. Available at: http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/MicrobiologyDevicesPanel/ucm388531.htm. Accessed July 15, 2014.
17. Wright TC Jr, Stoler MH, Behrens CM, Apple R, Derion T, Wright TL,. The ATHENA human papillomavirus study: design, methods, and baseline results. Am J Obstet Gynecol. 2012; 206: 46.e1-46.e11.
18. College of American Pathologists (CAP). CAP Accreditation Checklists. Northfield, IL: College of American Pathologists; 2014. Available at: http://www.cap.org/accreditation. Accessed July 15, 2014.
19. Cormier K, Schaaf M, Hamilton S, Tickman RJ, Perez-Reyes N, Sturgis CD,. NILM Pap slides from women 30 years of age and older with positive high-risk HPV DNA. Focused rescreening prior to report issuance, an enhanced quality control measure. Am J Clin Pathol. 2014; 141: 494-500.
20. HPV primary screening for cervical cancer-an interview with Ritu Nayar, MD [serial online]. CAP Today. Available at: http://www.captodayonline.com/hpv-primary-screening-for-cervical-cancer-an-interview-with-ritu-nayar-md/. Accessed July 15, 2014.
21. Cytopathology Education and Technology Consortium (CETC). Letter to the FDA regarding PMA hearing for HPV primary screening, February 27, 2014 [p. 179]. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/MicrobiologyDevicesPanel/UCM393482.pdf. Accessed July 15, 2014.
22. Huh W, Ault K, Chelmow D, et al., Use of Primary High Risk Human Papillomavirus Testing for Cervical Cancer Screening: Interim Clinical Guidance. In press.
23. Roche Molecular Systems. Cobas HPV test labeling [draft package insert]. Available at: http://www.accessdata.fda.gov/cdrh-docs/pdf10/P100020c.pdf. Accessed July 15, 2014.
24. Gibson JS,. Nucleic acid-based assays for the detection of high-risk human papillomavirus: a technical review [published online ahead of print June 17, 2014]. Cancer Cytopathol. doi: 10.1002/cncy.21451.
25. Moriarty AT, Clayton AC, Zaleskia S, et al., Unsatisfactory reporting rates: 2006 practices of participants in the College of American Pathologists Interlaboratory Comparison Program in Gynecologic Cytology. Arch Pathol Lab Med. 2009; 133: 1912-1916.
26. Zhao C, Austin RM,. High-risk human papillomavirus DNA test results are useful for disease risk stratification with unsatisfactory liquid-based cytology Pap test results. J Low Genit Tract Dis. 2009; 13: 79-84.
27. Rossi G, Carozzi F, Collina G, et al., HPV testing is an efficient management choice for women with inadequate liquid-based cytology in cervical cancer screening. Am J Clin Pathol. 2012 138: 65-71.
28. Zhao L, Wentzensen N, Zhang RR, et al., Factors associated with reduced accuracy in Papanicolaou test for patients with invasive cervical cancer [published online ahead of print May 28, 2014]. Cancer Cytopathol. doi: 10.1002/cncy.21443.
29. Ransdell JS, Davey DD, Zaleski S,. Clinicopathologic correlation of the unsatisfactory Papanicolaou smear. Cancer Cytopathol. 1997; 81: 139-143.
30. Alsharif M, McKeon DM, Gulbahce HE, Savik K, Pambuccian SE,. Unsatisfactory SurePath liquid-based Papanicolaou tests: causes and significance. Cancer Cytopathol. 2009; 117: 15-26.
31. Siebers AG, Klinkhamer PJ, Vedder JEM, Arbyn M, Bulten J,. Causes and relevance of unsatisfactory and satisfactory but limited smear of liquid based compared with conventional cervical cytology. Arch Pathol Lab Med. 2012; 136: 76-83.
32. Massad LS, Einstein MH, Huh WK, et al., 2012 Updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. 2012 ASCCP Consensus Guidelines Conference. Obstet Gynecol. 2013; 121: 829-846.
33. Can NT, Tesic V, Antic T,. Human papillomavirus testing in patients with invasive cervical carcinoma: an institutional experience. J Am Soc Cytopathol. 2014; 3: 126-130.
34. Hopenhayn C, Christian A, Christian W, et al., Prevalence of human papillomavirus types in invasive cervical cancers from 7 US cancer registries before vaccine introduction. J Low Genit Tract Dis. 2014; 18: 182-189.
35. Zhao C, Yang H, Li Z,. Cytopathology and more: evidence emerging for HPV-negative cervical cancer [serial online]. CAP Today. Available at: http://www.captodayonline.com/cytopathology-and-more-evidence-emerging-for-hpv-negative-cervical-cancer/. Accessed July 15, 2014.
36. Zhao C, Li Z, Nayar R, et al., Prior high-risk human papillomavirus testing and Papanicolaou test results of 70 invasive cervical carcinomas diagnosed in 2012: results of a retrospective multicenter study [published online ahead of print April 2, 2014]. Arch Pathol Lab Med. 2014.
37. Kitchener HC, Almonte M, Gilham C, et al., ARTISTIC: a randomized trial of human papillomavirus (HPV) testing in primary cervical screening. Health Technol Assess. 2009; 13: 1-150, iii-iv.
38. Farnsworth A,. Screening for the prevention of cervical cancer in the era of human papillomavirus vaccination: an Australian perspective. Acta Cytol. 2011; 55: 307-312.
39. de Sanjose S, Quint WG, Alemany L, et al., Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010; 11: 1048-1056.
40. Kinney W, Poitras N, Fetterman B, Lorey T,. Magnitude of increased lifetime risk of cervical cancer and death from cervical cancer with new screening recommendations [poster 93]. Poster presented at: Society of Gynecologic Oncology 45th Annual Meeting on Women's Cancer; March 22-25, 2014; Tampa, Florida. Available at: https://www.sgo.org/wp-content/uploads/2014/03/ABSUPP-3.14.14.pdf. Accessed March 22, 2014.
41. Gage JC, Schiffman M, Katki HA, et al., Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test [serial online]. J Natl Cancer Inst. 2014. doi: 10.1093/jnci/dju153.
42. Gage JC, Katki HA, Schiffman M, et al., The low risk of precancer after a screening result of human papillomavirus-negative/atypical squamous cells of undetermined significance Papanicolaou and implications for clinical management. Cancer Cytopathol. 2014. doi: 10.1002/cncy.21463.
43. Perkins R, Anderson B, Gorin S, Schulkin J,. Challenges in cervical cancer prevention: a survey of US obstetrician-gynecologists. Am J Prev Med. 2013; 45: 175-181.
44. American Cancer Society: Cancer Facts & Figures 2014. Atlanta, GA: American Cancer Society; 2014.
45. Rositch AF, Nowak RG, Gravitt PE,. Increased age and race-specific incidence of cervical cancer after correction for hysterectomy prevalence in the United States from 2000 to 2009. Cancer. 2014; 120: 2032-2038.
46. Stokley S, Jeyarajah J, Yankey D, et al., Immunization Services Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014-United States. MMWR Morb Mortal Wkly Rep. 2014; 63: 620-624.
47. American Society of Cytopathology Guidelines and Position Statements. Cervical Cancer Screening and Prevention. Available at: http://www.cytopathology.org/asc-guidelines/. Accessed July 15, 2014.